# US 2019/0240169 A1 · Pharmaceutical compositions and methods utilizing a d-amino acid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0240169 A1
- Document ID: US20190240169A1
- Status: Published application
- Kind: A1
- Application number: 16/389,959
- Filed: 2019-04-21
- Published: 2019-08-08
- Earliest claimed: 2008-01-08
- Assignees: Aas, LLC
- Inventors: Daniel Javitt
- Web page: https://patentgrep.com/patent/US20190240169A1

## CPC

- A61K 31/133: having hydroxy groups, e.g. sphingosine
- A61K 31/145: having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) (isothiourea A61K31/155)
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a pharmaceutical composition for oral administration comprising a D-amino acid combined with an antioxidant selected from the group consisting of vitamin E, vitamin C, a glutathione or a precursor thereof.

## Claims

### Claim 1

A pharmaceutical composition, comprising:
D-serine; and
a nephrotoxicity-reducing amount of L-cysteine,
wherein the ratio between the D-serine and the L-cysteine is between 2:1 and 1:1, and
wherein the pharmaceutical composition is formulated for oral administration.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, further comprising a nephrotoxicity reducing amount of N-acetyl-L-cysteine.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, further comprising at least one of vitamin E and vitamin C.

### Claim 4 (depends on 2)

The pharmaceutical composition of claim 2, further comprising at least one of vitamin E and vitamin C.

### Claim 5

A method for treating a neuropsychiatric disorder characterized by attenuated NMDA neurotransmission in a patient, the method comprising:
orally administering to the patient:
a therapeutically effective amount of D-serine; and
a nephrotoxicity-reducing effective amount of L-cysteine.

### Claim 6 (depends on 5)

The method of claim 5, further comprising orally administering to the patient a nephrotoxicity-reducing effective amount of N-acetyl-L-cysteine.

### Claim 7 (depends on 5)

The method of claim 5, further comprising administering to the patent at least one of an effective amount of vitamin E and vitamin C.

### Claim 8 (depends on 6)

The method of claim 6, further comprising administering to the patent at least one of an effective amount of vitamin E and vitamin C.

### Claim 9 (depends on 5)

The method of claim 5, wherein the ratio between the D-serine and the L-cysteine administered to the patient is between 2:1 and 1:1.

### Claim 10 (depends on 5)

The method of claim 5, wherein the D-serine and the L-cysteine are provided in a combined composition.

### Claim 11 (depends on 6)

The method of claim 6, wherein the D-serine, the L-cysteine, and the N-acetyl-L-cysteine are provided in a combined composition.

### Claim 12 (depends on 5)

The method of claim 5, wherein the neuropsychiatric disease is schizophrenia.
